Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 13/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8995496 | 0.84 | ESR1 (0.38) | ESR1SLC6A2SLC6A4ACP3CYP3A4 | |
| SCHEMBL13076103 | 0.80 | ESR1 (0.41) | ESR1SLC6A2SLC6A4ACP3CYP3A4 | |
| SCHEMBL5726722 | 0.78 | CYP19A1 (0.45) | ESR1SLC6A2SLC6A4ACP3CYP3A4 | |
| SCHEMBL7592215 | 0.77 | ESR1 (0.41) | ESR1SLC6A2SLC6A4ACP3 | |
| SCHEMBL8286102 | 0.76 | ESR1 (0.43) | ESR1SLC6A2SLC6A4ACP3CYP3A4 | |
| SCHEMBL21714670 | 0.74 | MAPT (0.43) | — | |
| SCHEMBL11628582 | 0.74 | ESR1 (0.42) | ESR1SLC6A2SLC6A4ACP3CYP3A4 | |
| SCHEMBL26809279 | 0.72 | CTSA (0.44) | CTSA | |
| SCHEMBL15787647 | 0.71 | ALDH1A1 (0.39) | SLC6A2SLC6A4CYP3A4CYP2D6 | |
| SCHEMBL15787286 | 0.71 | ALDH1A1 (0.39) | SLC6A2SLC6A4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188123-B2 | (Pyrrolidin-2-yl)phenyl derivatives | MERCK SHARP & DOHME B.V. (NL) | 2012-05-29 | — | — | US | disclosed |
| US-20100113493-A1 | (PYRROLIDIN-2-YL)PHENYL DERIVATIVES | N.V. ORGANON | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113493-A1 | (PYRROLIDIN-2-YL)PHENYL DERIVATIVES | CNR1, CNR2, TRPV1 | ESR1 3571/4885SLC6A2 2196/4885SLC6A4 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.